Targeting myocardial substrate metabolism in heart failure: potential for new therapies
Identifieur interne : 000202 ( Istex/Checkpoint ); précédent : 000201; suivant : 000203Targeting myocardial substrate metabolism in heart failure: potential for new therapies
Auteurs : Hossein Ardehali [États-Unis] ; Hani N. Sabbah [États-Unis] ; Michael A. Burke [États-Unis] ; Satyam Sarma [États-Unis] ; Peter P. Liu [Canada] ; John G. F. Cleland [Royaume-Uni] ; Aldo Maggioni [Italie] ; Gregg C. Fonarow [États-Unis] ; E. Dale Abel [États-Unis] ; Umberto Campia [États-Unis] ; Mihai Gheorghiade [États-Unis]Source :
- European Journal of Heart Failure [ 1388-9842 ] ; 2012-02.
Abstract
The incidence and prevalence of heart failure have increased significantly over the past few decades. Available data suggest that patients with heart failure independent of the aetiology have viable but dysfunctional myocardium that is potentially salvageable. Although a great deal of research effort has focused on characterizing the molecular basis of heart failure, cardiac metabolism in this disorder remains an understudied discipline. It is known that many aspects of cardiomyocyte energetics are altered in heart failure. These include a shift from fatty acid to glucose as a preferred substrate and a decline in the levels of ATP. Despite these demonstrated changes, there are currently no approved drugs that target metabolic enzymes or proteins in heart failure. This is partly due to our limited knowledge of the mechanisms and pathways that regulate cardiac metabolism. Better characterization of these pathways may potentially lead to new therapies for heart failure. Targeting myocardial energetics in the viable and potentially salvageable tissue may be particularly effective in the treatment of heart failure. Here, we will review metabolic changes that occur in fatty acid and glucose metabolism and AMP‐activated kinase in heart failure. We propose that cardiac energetics should be considered as a potential target for therapy in heart failure and more research should be done in this area.
Url:
DOI: 10.1093/eurjhf/hfr173
Affiliations:
- Canada, Italie, Royaume-Uni, États-Unis
- Californie, Illinois, Ontario
- Chicago, Los Angeles, Toronto
- Université de Toronto
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:9EB3FD1C2BE0DBF2A128C4434511AED3DADD5663Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Targeting myocardial substrate metabolism in heart failure: potential for new therapies</title><author><name sortKey="Ardehali, Hossein" sort="Ardehali, Hossein" uniqKey="Ardehali H" first="Hossein" last="Ardehali">Hossein Ardehali</name></author><author><name sortKey="Sabbah, Hani N" sort="Sabbah, Hani N" uniqKey="Sabbah H" first="Hani N." last="Sabbah">Hani N. Sabbah</name></author><author><name sortKey="Burke, Michael A" sort="Burke, Michael A" uniqKey="Burke M" first="Michael A." last="Burke">Michael A. Burke</name></author><author><name sortKey="Sarma, Satyam" sort="Sarma, Satyam" uniqKey="Sarma S" first="Satyam" last="Sarma">Satyam Sarma</name></author><author><name sortKey="Liu, Peter P" sort="Liu, Peter P" uniqKey="Liu P" first="Peter P." last="Liu">Peter P. Liu</name></author><author><name sortKey="Cleland, John G F" sort="Cleland, John G F" uniqKey="Cleland J" first="John G. F." last="Cleland">John G. F. Cleland</name></author><author><name sortKey="Maggioni, Aldo" sort="Maggioni, Aldo" uniqKey="Maggioni A" first="Aldo" last="Maggioni">Aldo Maggioni</name></author><author><name sortKey="Fonarow, Gregg C" sort="Fonarow, Gregg C" uniqKey="Fonarow G" first="Gregg C." last="Fonarow">Gregg C. Fonarow</name></author><author><name sortKey="Abel, E Dale" sort="Abel, E Dale" uniqKey="Abel E" first="E. Dale" last="Abel">E. Dale Abel</name></author><author><name sortKey="Campia, Umberto" sort="Campia, Umberto" uniqKey="Campia U" first="Umberto" last="Campia">Umberto Campia</name></author><author><name sortKey="Gheorghiade, Mihai" sort="Gheorghiade, Mihai" uniqKey="Gheorghiade M" first="Mihai" last="Gheorghiade">Mihai Gheorghiade</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9EB3FD1C2BE0DBF2A128C4434511AED3DADD5663</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1093/eurjhf/hfr173</idno><idno type="url">https://api-v5.istex.fr/document/9EB3FD1C2BE0DBF2A128C4434511AED3DADD5663/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002A93</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002A93</idno><idno type="wicri:Area/Istex/Curation">002A93</idno><idno type="wicri:Area/Istex/Checkpoint">000202</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000202</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Targeting myocardial substrate metabolism in heart failure: potential for new therapies</title><author><name sortKey="Ardehali, Hossein" sort="Ardehali, Hossein" uniqKey="Ardehali H" first="Hossein" last="Ardehali">Hossein Ardehali</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, IL, Chicago</wicri:regionArea><placeName><settlement type="city">Chicago</settlement><region type="state">Illinois</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation></author><author><name sortKey="Sabbah, Hani N" sort="Sabbah, Hani N" uniqKey="Sabbah H" first="Hani N." last="Sabbah">Hani N. Sabbah</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Henry Ford Health System, MI, Detroit</wicri:regionArea><wicri:noRegion>Detroit</wicri:noRegion></affiliation></author><author><name sortKey="Burke, Michael A" sort="Burke, Michael A" uniqKey="Burke M" first="Michael A." last="Burke">Michael A. Burke</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, IL, Chicago</wicri:regionArea><placeName><settlement type="city">Chicago</settlement><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Sarma, Satyam" sort="Sarma, Satyam" uniqKey="Sarma S" first="Satyam" last="Sarma">Satyam Sarma</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, IL, Chicago</wicri:regionArea><placeName><settlement type="city">Chicago</settlement><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Liu, Peter P" sort="Liu, Peter P" uniqKey="Liu P" first="Peter P." last="Liu">Peter P. Liu</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Cleland, John G F" sort="Cleland, John G F" uniqKey="Cleland J" first="John G. F." last="Cleland">John G. F. Cleland</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Cardiovascular and Respiratory Studies, Hull York Medical School, University of Hull, Kingston‐upon‐Hull</wicri:regionArea><wicri:noRegion>Kingston‐upon‐Hull</wicri:noRegion></affiliation></author><author><name sortKey="Maggioni, Aldo" sort="Maggioni, Aldo" uniqKey="Maggioni A" first="Aldo" last="Maggioni">Aldo Maggioni</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>ANMCO Research Center, Florence</wicri:regionArea><wicri:noRegion>Florence</wicri:noRegion></affiliation></author><author><name sortKey="Fonarow, Gregg C" sort="Fonarow, Gregg C" uniqKey="Fonarow G" first="Gregg C." last="Fonarow">Gregg C. Fonarow</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of California, CA, Los Angeles</wicri:regionArea><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Abel, E Dale" sort="Abel, E Dale" uniqKey="Abel E" first="E. Dale" last="Abel">E. Dale Abel</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Endocrinology, Department of Medicine, University of Utah, Salt Lake City</wicri:regionArea><wicri:noRegion>Salt Lake City</wicri:noRegion></affiliation></author><author><name sortKey="Campia, Umberto" sort="Campia, Umberto" uniqKey="Campia U" first="Umberto" last="Campia">Umberto Campia</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, IL, Chicago</wicri:regionArea><placeName><settlement type="city">Chicago</settlement><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Gheorghiade, Mihai" sort="Gheorghiade, Mihai" uniqKey="Gheorghiade M" first="Mihai" last="Gheorghiade">Mihai Gheorghiade</name><affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, IL, Chicago</wicri:regionArea><placeName><settlement type="city">Chicago</settlement><region type="state">Illinois</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Heart Failure</title><title level="j" type="abbrev">European Journal of Heart Failure</title><idno type="ISSN">1388-9842</idno><idno type="eISSN">1879-0844</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2012-02">2012-02</date><biblScope unit="volume">14</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="120">120</biblScope><biblScope unit="page" to="129">129</biblScope></imprint><idno type="ISSN">1388-9842</idno></series><idno type="istex">9EB3FD1C2BE0DBF2A128C4434511AED3DADD5663</idno><idno type="DOI">10.1093/eurjhf/hfr173</idno><idno type="ArticleID">EJHFHFR173</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1388-9842</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">The incidence and prevalence of heart failure have increased significantly over the past few decades. Available data suggest that patients with heart failure independent of the aetiology have viable but dysfunctional myocardium that is potentially salvageable. Although a great deal of research effort has focused on characterizing the molecular basis of heart failure, cardiac metabolism in this disorder remains an understudied discipline. It is known that many aspects of cardiomyocyte energetics are altered in heart failure. These include a shift from fatty acid to glucose as a preferred substrate and a decline in the levels of ATP. Despite these demonstrated changes, there are currently no approved drugs that target metabolic enzymes or proteins in heart failure. This is partly due to our limited knowledge of the mechanisms and pathways that regulate cardiac metabolism. Better characterization of these pathways may potentially lead to new therapies for heart failure. Targeting myocardial energetics in the viable and potentially salvageable tissue may be particularly effective in the treatment of heart failure. Here, we will review metabolic changes that occur in fatty acid and glucose metabolism and AMP‐activated kinase in heart failure. We propose that cardiac energetics should be considered as a potential target for therapy in heart failure and more research should be done in this area.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Italie</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Californie</li><li>Illinois</li><li>Ontario</li></region><settlement><li>Chicago</li><li>Los Angeles</li><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="États-Unis"><region name="Illinois"><name sortKey="Ardehali, Hossein" sort="Ardehali, Hossein" uniqKey="Ardehali H" first="Hossein" last="Ardehali">Hossein Ardehali</name></region><name sortKey="Abel, E Dale" sort="Abel, E Dale" uniqKey="Abel E" first="E. Dale" last="Abel">E. Dale Abel</name><name sortKey="Ardehali, Hossein" sort="Ardehali, Hossein" uniqKey="Ardehali H" first="Hossein" last="Ardehali">Hossein Ardehali</name><name sortKey="Burke, Michael A" sort="Burke, Michael A" uniqKey="Burke M" first="Michael A." last="Burke">Michael A. Burke</name><name sortKey="Campia, Umberto" sort="Campia, Umberto" uniqKey="Campia U" first="Umberto" last="Campia">Umberto Campia</name><name sortKey="Fonarow, Gregg C" sort="Fonarow, Gregg C" uniqKey="Fonarow G" first="Gregg C." last="Fonarow">Gregg C. Fonarow</name><name sortKey="Gheorghiade, Mihai" sort="Gheorghiade, Mihai" uniqKey="Gheorghiade M" first="Mihai" last="Gheorghiade">Mihai Gheorghiade</name><name sortKey="Sabbah, Hani N" sort="Sabbah, Hani N" uniqKey="Sabbah H" first="Hani N." last="Sabbah">Hani N. Sabbah</name><name sortKey="Sarma, Satyam" sort="Sarma, Satyam" uniqKey="Sarma S" first="Satyam" last="Sarma">Satyam Sarma</name></country><country name="Canada"><region name="Ontario"><name sortKey="Liu, Peter P" sort="Liu, Peter P" uniqKey="Liu P" first="Peter P." last="Liu">Peter P. Liu</name></region></country><country name="Royaume-Uni"><noRegion><name sortKey="Cleland, John G F" sort="Cleland, John G F" uniqKey="Cleland J" first="John G. F." last="Cleland">John G. F. Cleland</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Maggioni, Aldo" sort="Maggioni, Aldo" uniqKey="Maggioni A" first="Aldo" last="Maggioni">Aldo Maggioni</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000202 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 000202 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Checkpoint
|type= RBID
|clé= ISTEX:9EB3FD1C2BE0DBF2A128C4434511AED3DADD5663
|texte= Targeting myocardial substrate metabolism in heart failure: potential for new therapies
}}
| This area was generated with Dilib version V0.6.29. |  |